6-(N-Acetylamino)-3-(4-ethylbenzyl)-1H-pyridin-2-one | 479481-28-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-(N-Acetylamino)-3-(4-ethylbenzyl)-1H-pyridin-2-one
• 英文别名: N-[5-[(4-ethylphenyl)methyl]-6-oxo-1H-pyridin-2-yl]acetamide
• CAS: 479481-28-2
• 化学式: C₁₆H₁₈N₂O₂
• 分子量: 270.331
• InChiKey: IHYURPFKYIARAR-UHFFFAOYSA-N

物化性质

• 沸点：
  560.3±50.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(N-Acetylamino)-3-(4-ethylbenzyl)-1H-pyridin-2-one 在 sodium hydroxide 、 水 作用下， 以 甲醇 为溶剂， 反应 22.0h， 生成 6-Amino-3-(4-ethylbenzyl)-1H-pyridin-2-one
  参考文献：
  名称：

  EP1405859

  摘要：

  公开号：
• 作为产物：
  描述：

  6-amino-3-(4-ethylbenzyl)-2-methoxypyridine 、 溶剂黄146 在 氢溴酸 作用下， 反应 2.0h， 生成 6-(N-Acetylamino)-3-(4-ethylbenzyl)-1H-pyridin-2-one
  参考文献：
  名称：

  EP1405859

  摘要：

  公开号：

文献信息

• Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor
  申请人：Nishimura Toshihiro

  公开号：US20050049203A1

  公开（公告）日：2005-03-03

  The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X 1 and X 3 independently represent N or CH; X 2 represents N or CR 2 ; X 4 represents N or CR 3 ; and with the proviso that one or two of X 1 , X 2 , X 3 and X 4 represent N; R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted(lower alkoxy) group, a lower alkoxy(lower alkoxy) -substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A—wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R 3 represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, or prodrugs thereof which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses and production intermediates thereof.

  本发明提供了一种以通式表示的含氮杂环衍生物： 其中，X1和X3独立地表示N或CH；X2表示N或CR2；X4表示N或CR3；并且假定X1、X2、X3和X4中的一个或两个表示N；R1表示氢原子、卤素原子、低碳基、低烷氧基、低硫代烷基、低烷氧基取代的（低烷基）基团、低烷氧基取代的（低烷氧基）基团、低烷氧基（低烷氧基）取代的（低烷基）基团、环状低烷基、卤素（低烷基）基团或由通式HO-A-表示的基团，其中A表示低碳亚烷基、低碳亚烷氧基或低碳亚烷硫基；R2表示氢原子、卤素原子、低碳基、环状低碳基、低烷氧基、氨基、（低酰基）氨基、单（低烷基）氨基或双（低烷基）氨基；R3表示氢原子或低碳基，或其药学上可接受的盐，或其前药，其作为预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂，包括这些药剂的制剂和制备中间体。
• Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same
  申请人：Kakinuma Hiroyuki

  公开号：US20060194809A1

  公开（公告）日：2006-08-31

  There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

  提供了下列公式的杂环基5-硫基-β-D-葡萄糖苷化合物，该化合物对SGLT2活性具有抑制作用，或其药学上可接受的盐或水合物。还提供了一种制药制剂，特别是预防或治疗糖尿病、糖尿病相关疾病或糖尿病并发症的药物，该制剂包含该化合物作为活性成分。
• Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US07271153B2

  公开（公告）日：2007-09-18

  The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 and X3 independently represent N or CH; X2 represents N or CR2; X4 represents N or CR3; and with the proviso that one or two of X1, X2, X3 and X4 represent N; R1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy(lower alkoxy)-substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A- wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R3 represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, or prodrugs thereof which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses and production intermediates thereof.

  本发明提供了一种由通式表示的含氮杂环衍生物： 其中X1和X3分别独立地表示N或CH；X2表示N或CR2；X4表示N或CR3；并且在X1、X2、X3和X4中的一个或两个表示N；R1表示氢原子、卤原子、低碳基、低烷氧基、低烷硫基、低烷氧基取代的（低碳基）基团、低烷氧基取代的（低烷氧基）基团、低烷氧基（低烷氧基）取代的（低碳基）基团、环状低碳基、卤（低碳基）基团或由通式HO-A-表示的基团，其中A表示低碳亚基、低碳亚氧基或低碳硫基；R2表示氢原子、卤原子、低碳基、环状低碳基、低烷氧基、氨基、（低酰基）氨基、单（低碳基）氨基或双（低碳基）氨基；R3表示氢原子或低碳基，或其药学上可接受的盐，或其前药，其用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂，以及包含它们的制药组合物和制药用途和中间体。
• NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1405859A1

  公开（公告）日：2004-04-07

  The present invention is to provide a nitrogen-containing heterocyclic derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof, which exerts an excellent inhibitory activity in human SGLT2 and is useful as an agent for the prevention or treatment of a disease associated with hyperglycemia such as diabetes etc., or a pharmaceutical composition comprising the same and a pharmaceutical use thereof and a production intermediate thereof. In the general formula (I), X1 and X3 are N or CH; X2 is N or CR2; X4 is N or CR3; and with the proviso that one or two of X1, X2, X3 and X4 are N; and R1, R2 and R3 are a hydrogen atom etc.

  本发明旨在提供一种由通式(I)代表的含氮杂环衍生物或其药学上可接受的盐，或其原药，该衍生物对人SGLT2具有优异的抑制活性，可作为预防或治疗糖尿病等与高血糖相关疾病的药物，或由其组成的药物组合物及其药物用途和其生产中间体。在通式（I）中，X1 和 X3 是 N 或 CH；X2 是 N 或 CR2；X4 是 N 或 CR3；但条件是 X1、X2、X3 和 X4 中的一个或两个是 N；R1、R2 和 R3 是氢原子等。
• HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1609799A1

  公开（公告）日：2005-12-28

  There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

  本发明提供了对 SGLT2 活性具有抑制作用的下式杂芳基 5-硫代-β-D-吡喃葡萄糖苷化合物，或其药学上可接受的盐或其水合物。本发明还提供了一种药物制剂，特别是糖尿病、糖尿病相关疾病或糖尿病并发症的预防或治疗药物，该药物制剂包含此类化合物作为活性成分。